Company

WuXi AppTec Q3 Revenue Jumps 38% as Backlog Hits RMB 76.74 Billion – Full-Year Guidance Raised
Finanical ReportsHKG: 2359

WuXi AppTec Q3 Revenue Jumps 38% as Backlog Hits RMB 76.74 Billion – Full-Year Guidance Raised

WuXi AppTec Co., Ltd. (SHA: 603259; HKG: 2359) released its 2026 third-quarter report, posting Q3 operating revenue of RMB 16.640 billion, up 38.01% year on year (YoY), and net profit…

HutchMed's SANOVO Phase III Hits Primary Endpoint – ORPATHYS Plus TAGRISSO Extends Median PFS to 24.9 Months in MET-Overexpressing EGFR-Mutant NSCLC

HutchMed’s SANOVO Phase III Hits Primary Endpoint – ORPATHYS Plus TAGRISSO Extends Median PFS to 24.9 Months in MET-Overexpressing EGFR-Mutant NSCLC

Regeneron Extends BARDA Agreement With $270 Million Inmazeb Supply Deal for U.S. Ebola Preparedness Through 2031

Regeneron Extends BARDA Agreement With $270 Million Inmazeb Supply Deal for U.S. Ebola Preparedness Through 2031

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Contact US
ProBio and Immunofoco Forge Global CGT Manufacturing Alliance
Genscript BiotechHKG: 1548

ProBio and Immunofoco Forge Global CGT Manufacturing Alliance

Stealth BioTherapeutics Receives FDA Accelerated Approval for Forzinity in Barth Syndrome
Product approvalsRare / orphan disease drugs

Stealth BioTherapeutics Receives FDA Accelerated Approval for Forzinity in Barth Syndrome

Genrix Bio Secures Exclusive Deal for Vecantoxatug and Silevimig with CMS
Genrix BiopharmaceuticalHKG: 0867

Genrix Bio Secures Exclusive Deal for Vecantoxatug and Silevimig with CMS

Roche’s SC Lunsumio Gains CHMP Recommendation for Relapsed Follicular Lymphoma
CancerOTCMKTS: RHHBY

Roche’s SC Lunsumio Gains CHMP Recommendation for Relapsed Follicular Lymphoma

Show More